Keytruda has been approved since 2016 as a second-line option after chemotherapy for patients with more advanced HNSCC that ...
The US Food and Drug Administration (FDA) has accepted Bristol Myers Squibb’s (BMS) supplemental biologics licence ...
MONECO Advisors LLC significantly increased its holdings in Bristol-Myers Squibb during the fourth quarter, nearly doubling ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback